David Melnick, M.D., Vice President Clinical Development , Anti-Infectives at Allergan Pharmaceuticals
joined us for World Anti-Microbial Resistance Congress USA 2015 to discuss
'Clinical development of ceftzadime-avibactam...Navigating an evolving regulatory environment.'
In this presentation, learn about
some of the effects of the changing regulatory environment on the clinical development of ceftazidime-avibactam
.
Download the presentation to understand more about:
-
Avycaz
-
Carbapenem-resistant Enterobacteriaceae (CRE)
-
Well-defined PK/PD Targets
...and
much
more!
Get your copy here!
To learn more about
navigating an evolving regulatory environment
, join us at
World Anti-Microbial Resistance Congress USA 2016
held
September 8-9
in
Washington, DC
.